Pharvaris N.V. (PHVS) is a publicly traded company in the Healthcare — Biotechnology industry listed on NASDAQ. This overview shows the latest price, key valuation ratios, profitability metrics and financial-health indicators used by fundamental investors.
Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases.
Is Pharvaris N.V. stock overvalued or undervalued in 2026?
As of October 30, 2026, Pharvaris N.V. (PHVS) trades at $33.53 with no positive earnings over the last twelve months, according to Kaplio. No valuation verdict: it has no earnings to calculate a P/E from.
Kaplio overview: Pharvaris N.V.
Market cap $2B · 52 weeks $22 – $39 (14 % below the high) · P/E no earnings · Dividend none · Next earnings November 11, 2026 · expected EPS $-0.82 · Closing price, Oct 30 · accounts published Aug 12.
- Valuation: P/E — (no earnings).
- Balance sheet: Safe zone (solid).
- Earnings: 3 of 8 (disappointing).
What would it be worth at its usual multiples?
No valuation verdict: it has no earnings to calculate a P/E from.
What matters in biotech: 2 of 4 pass
- R&D / Market cap 0.0 %, fails.
- Market cap / Cash 6.8×, fails.
- Cash Runway 26 meses, passes, near the threshold.
- Total Debt 0.0×, passes.
- Annual cash burn $2.32, info.
Against its peers (reference peers) — Pharvaris N.V.: P/E —; EV/EBITDA —; ROIC -60.7 %; $2.3B. BioMarin Pharmaceutical Inc. (P/E 150×; EV/EBITDA 38.0×; ROIC 1.2 %; $11.3B), Harmony Biosciences Holdings, Inc. (P/E 12.6×; EV/EBITDA 6.7×; ROIC 15.0 %; $2.3B), Aurinia Pharmaceuticals Inc. (P/E 7.3×; EV/EBITDA 11.4×; ROIC 20.9 %; $2.2B).
Profitability
| Return on Equity | -61.24% |
| Return on Invested Capital | -60.72% |
| Return on Assets | -52.20% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Financial Health
| Debt / Equity | 0.00 |
| Current Ratio | 11.94 |
| Piotroski F-Score | 1 |
| Altman Z-Score | 24.30 |
Price Performance
| 1 month | +7.50% |
| 3 months | +3.97% |
| Year-to-date | +20.83% |
| 1 year | +50.90% |
| 3 years | +95.17% |
| 5 years | +105.71% |
Related companies: BMRN · VERA · TVTX · BCRX
Explore sector: Healthcare · Biotechnology
More sections of PHVS: Financials · Valuation · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method today · Companies that pass the Lynch method today · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks